Scholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) Current ratio
Scholar Rock Holding Corporation's current ratio at the end of the quarter to 30 June 2026 was 7.0×, up 0.1× from fiscal 2025 (6.9×). Over the past ten years it has ranged from 4.1× (fiscal 2021) to 11.8× (fiscal 2017); the current reading is higher than 40% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 6.9× | (27.70%) |
| FY2024 | 9.6× | 9.20% |
| FY2023 | 8.8× | (2.35%) |
| FY2022 | 9.0× | 118.45% |
| FY2021 | 4.1× | (49.00%) |
| FY2020 | 8.1× | 43.39% |
| FY2019 | 5.6× | (1.30%) |
| FY2018 | 5.7× | (51.48%) |
| FY2017 | 11.8× | 24.30% |
| FY2016 | 9.5× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 7.0× | (18.74%) |
| Mar 2026 | 8.6× | 24.31% |
| Dec 2025 | 6.9× | 10.23% |
| Sep 2025 | 6.3× | (0.36%) |
| 30 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| MANE Veradermics Incorporated compare | 70.5× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 33.6× |
| CGON CG Oncology, Inc. compare | 22.2× |
| COGT Cogent Biosciences, Inc. compare | 13.6× |
| ERAS Erasca, Inc. compare | 8.3× |
| IMVT Immunovant, Inc. compare | 7.3× |
| SRRK Scholar Rock Holding Corporation | 7.0× |
| PTCT PTC Therapeutics, Inc. compare | 3.3× |
| KOD Kodiak Sciences Inc. compare | 2.5× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement